May 30, 2023 7:00am EDT Tonix Pharmaceuticals Announces Presentation at the 2023 BIO International Convention
May 25, 2023 4:05pm EDT Tonix Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
May 25, 2023 7:00am EDT Tonix Pharmaceuticals Announces Poster Presentation at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
May 23, 2023 7:00am EDT Tonix Pharmaceuticals Announces the Isolation and Characterization of the (S)-Isomer of Tianeptine, TNX-4300 (Estianeptine), Now Under Development for Psychiatric and Neurodegenerative Diseases
May 22, 2023 7:00am EDT Tonix Pharmaceuticals Announces Clinical Proof-of-Concept Study of TNX-1900 (Intranasal Potentiated Oxytocin)
May 18, 2023 7:00am EDT Tonix Pharmaceuticals to Participate in the A.G.P. Virtual Healthcare Conference
May 17, 2023 7:00am EDT Tonix Pharmaceuticals Announces Pharmacology and Medicinal Chemistry Results that Reveal the Molecular Mechanism of Action of Tianeptine, the Active Ingredient of TNX-601 ER, in Treating Depression
May 8, 2023 7:00am EDT Tonix Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Highlights
